Journal Watch · Journal of Medicinal Chemistry · 2026

Three Nitrogen Atoms Turn Old Kinase Inhibitors Into New Targetable Remedy.

Our findings introduce a novel light-targeted pharmacological approach exploiting the natural light focusing anatomy of the eye.

Besztercei B, Antal R, Tähtivaara L et al.Journal of Medicinal Chemistry3 min readPharma relevance 60/100

DOI: 10.1021/acs.jmedchem.6c01380PMID: 42911703Study type: preclinical (animal / model) study

TL;DR

Our findings introduce a novel light-targeted pharmacological approach exploiting the natural light focusing anatomy of the eye.

Key findings

  • In vivo, orally administered EYE1090 and EYE1118 suppressed VEGF-induced retinal leakage in rats and reduced lesion size in a mouse model of choroidal neovascularization, but did not show acute hepatotoxicity.
  • Our findings introduce a novel light-targeted pharmacological approach exploiting the natural light focusing anatomy of the eye.

What they did

Azido-functionalization in these molecules enables light-triggered receptor binding while preserving potent inhibition in the dark. Both compounds exhibit significantly enhanced activity upon exposure to green light that reaches the human retina, also in the elderly. In vitro, the compounds robustly inhibited angiogenesis and endothelial migration that was further potentiated by light.

Full abstract (original)

Background: Pathological neovascularization in the eye is a significant contributor to vision loss in diseases such as age-related macular degeneration and diabetic retinopathy. While anti-VEGF biologics are effective, they require repeated intravitreal injections. Here, we report a novel principle for designing photoactivatable VEGFR2 inhibitors, along with two examples, EYE1090 and EYE1118.

What they did: Azido-functionalization in these molecules enables light-triggered receptor binding while preserving potent inhibition in the dark. Both compounds exhibit significantly enhanced activity upon exposure to green light that reaches the human retina, also in the elderly. In vitro, the compounds robustly inhibited angiogenesis and endothelial migration that was further potentiated by light.

Results & conclusions: In vivo, orally administered EYE1090 and EYE1118 suppressed VEGF-induced retinal leakage in rats and reduced lesion size in a mouse model of choroidal neovascularization, but did not show acute hepatotoxicity. Our findings introduce a novel light-targeted pharmacological approach exploiting the natural light focusing anatomy of the eye.

Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.6c01380 · PubMed 42911703.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology · small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal of Medicinal Chemistry study find?

Our findings introduce a novel light-targeted pharmacological approach exploiting the natural light focusing anatomy of the eye.

What type of study is this?

It is a preclinical (animal / model) study, published in Journal of Medicinal Chemistry in 2026. Azido-functionalization in these molecules enables light-triggered receptor binding while preserving potent inhibition in the dark.

Where can I read the original paper?

The original is at the publisher via DOI 10.1021/acs.jmedchem.6c01380. PubMed ID: 42911703. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Besztercei B, Antal R, Tähtivaara L et al.. Three Nitrogen Atoms Turn Old Kinase Inhibitors Into New Targetable Remedy.. Journal of Medicinal Chemistry (2026). DOI: 10.1021/acs.jmedchem.6c01380.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/three-nitrogen-atoms-turn-old-kinase-inhibitors-into-new-targetable-reme-c01380/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides